Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

被引：0
|
作者：
Xinmin Zhao
Xiaofeng Xu
Qunling Zhang
Zhen Jia
Si Sun
Jian Zhang
Biyun Wang
Zhonghua Wang
Xichun Hu
机构：
[1] Fudan University,Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College
[2] Fudan University,Department of Clinical Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College
来源：
BMC Cancer | / 11卷
关键词：
Advanced breast cancer; bone metastases; zoledronic acid; VEGF; N-telopeptide; prognosis; predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Faruk Tas
    Derya Duranyildiz
    Hilal Oguz
    Hakan Camlica
    Vildan Yasasever
    Erkan Topuz
    Medical Oncology, 2008, 25 : 346 - 349
  • [32] The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
    Hadji, Peyman
    Ziller, May
    Maurer, Tobias
    Autenrieth, Michael
    Muth, Mathias
    Ruebel, Amelie
    May, Christoph
    Birkholz, Katrin
    Diebel, Erhardt
    Gleissner, Jochen
    Rothe, Peter
    Gschwend, Juergen E.
    JOURNAL OF BONE ONCOLOGY, 2012, 1 (03) : 88 - 94
  • [33] Effects of zoledronic acid on serum levels of MMPs and bone remodeling markers in breast cancer patients with bone metastases
    Kanakis, I
    Nikolaou, M
    Kiamouris, C
    Pectasides, D
    Karamanos, N
    FEBS JOURNAL, 2005, 272 : 270 - 270
  • [34] LONG-TERM SAFETY OF ZOLEDRONIC ACID FOR BREAST CANCER WITH BONE METASTASES
    Taira, Shinichiro
    Takahashi, Shunji
    Ito, Yoshinori
    Tokudome, Nahomi
    Tsutsumi, Chizuko
    Kobayashi, Kokoro
    Fukuda, Takayo
    Asai, Hiroaki
    Oto, Masahumi
    Ito, Mayuko
    Hatake, Kiyohiko
    ANNALS OF ONCOLOGY, 2010, 21 : 21 - 21
  • [35] Clinical features and prognostic factors for patients with bone metastases from prostate cancer
    He, Jian
    Zeng, Zhao-Chong
    Yang, Ping
    Chen, Bing
    Jiang, We
    Du, Shi-Suo
    ASIAN JOURNAL OF ANDROLOGY, 2012, 14 (03) : 505 - 508
  • [36] NTX and VEGF in cancer patients with bone metastases treated with zoledronic acid
    Mercatali, L.
    Ibrahim, T.
    Sacanna, E.
    Ricci, R.
    Scarpi, E.
    Fabbri, F.
    Serra, P.
    Tison, C.
    Amadori, D.
    EJC SUPPLEMENTS, 2010, 8 (05): : 23 - 23
  • [37] HEALTH RESOURCE UTILIZATION OF SUBJECTS RECEIVING DENOSUMAB AND ZOLEDRONIC ACID IN A RANDOMIZED PHASE 3 TRIAL OF ADVANCED BREAST CANCER PATIENTS WITH BONE METASTASES
    Body, J. J.
    von Moos, R.
    Stopeck, A.
    Qian, Y.
    Braun, A.
    Chung, K.
    VALUE IN HEALTH, 2010, 13 (07) : A279 - A279
  • [38] Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
    Xu, Yaqian
    Wang, Yan
    Yuan, Chenwei
    Sheng, Xiaonan
    Sha, Rui
    Dai, Huijuan
    Zhang, Shan
    Wang, Yaohui
    Lin, Yanping
    Zhou, Liheng
    Xu, Shuguang
    Zhang, Jie
    Yin, Wenjin
    Lu, Jinsong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [39] Predictive and Prognostic Value of Inflammatory and Nutritional Indexes in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
    Arici, Mustafa Ozgur
    Salim, Derya Kivrak
    Kocer, Murat
    Alparslan, Ahmet Sukru
    Karakas, Baris Rafet
    Ozturk, Banu
    MEDICINA-LITHUANIA, 2024, 60 (11):
  • [40] Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases
    Niikura, Naoki
    Liu, Jun
    Hayashi, Naoki
    Palla, Shana L.
    Tokuda, Yutaka
    Hortobagyi, Gabriel N.
    Ueno, Naoto T.
    Theriault, Richard L.
    CANCER, 2012, 118 (08) : 2039 - 2047
12345